Cholinergic receptors and neurodegenerative diseases

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 85-89

  Gualtieri, Fulvio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholine releasers; Acetylcholinesterase inhibitors; Alzheimer's disease; Cholinergic hypothesis; High affinity choline uptake enhancers; Muscarinic agonists; Muscarinic antagonists; Neurodegenerative diseases; Nicotinic agonists; Parkinson's disease

Indexed keywords

2 (2 OXO 1 PYRROLIDINYL) N (5,6,7,8 TETRAHYDRO 2,3 DIMETHYLFURO[2,3 B]QUINOLIN 4 YL)ACETAMIDE; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (4 BUTYLTHIO 1,2,5 THIADIAZOL 3 YL)QUINUCLIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 CYCLOHEXYL ALPHA [4 [(4 METHOXYPHENYL)SULFINYL]PHENYL] 1 PIPERAZINEACETONITRILE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ALVAMELINE; AMYLOID BETA PROTEIN; BIBN 99; CEVIMELINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; LINOPIRDINE; METRIFONATE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR ANTAGONIST; NICOTINIC AGENT; RIVASTIGMINE; SABCOMELINE; SM 21; TACRINE; TALSACLIDINE; UNCLASSIFIED DRUG; XAMOMELINE; Z 4105; ZIFROSILONE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG DEVELOPMENT; HUMAN;

ANIMALS; CHOLINERGIC AGENTS; HUMANS; NEURODEGENERATIVE DISEASES; RECEPTORS, CHOLINERGIC;

EID: 0034126165     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00021-7     Document Type: Conference Paper

References (23)

1. Anonymous, 1995. Z-4105. Drugs of the Future, 20, 584.
2. Anonymous, 1999. Sabcomeline hydrochloride. Drugs of the Future, 24, 113-114.
3. Bartus R.T., Dean R.L.I., Beer A.S., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunctions. Science. 217:1982;408-417.
4. Bowen D.M., Smith C.B., White P., Davidson A.N. Neurotransmitter related enzymes and indexes of hypoxia in senile dementia and other abiothrophies. Brain. 99:1976;459-496.
5. Boyd R.T. The molecular biology of neuronal nicotinic acetylcholine receptors. Crit. Rev. Toxicol. 27:1997;299-318.
6. Brioni J.D., Morgan S.J., Oneill A.B., Sykora T.M., Postl S.P., Pan J.B., Sullivan J.P., Arneric S.P. In vivo profile of novel nicotinic ligands with CNS selectivity. Med. Chem. Res. 6:1996;487-510.
7. Chaki H., Yamabe H., Sugano M., Morita S., Bessho T., Tabata R., K.-I. S., Egawa M., Tobe A., Morinaka Y. Design and synthesis of 4-acylaminopyridine derivatives: novel high affinity choline uptake enhancers II. Bioorg. Med. Chem. Lett. 5:1995;1495-1500.
8. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal acetylcholine receptors h-α-2-β-2, h-α-2-β-4, h-α-3-β-2, h-α-4-β-2, h-α-4-β-4 and h-α-7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280:1997;346-356.
9. Coyle J.T., Price C.L., De Long M.R. Alzheimer's disease: a disorder of cortical cholinergic innervations. Science. 219:1983;1184-1190.
10. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403-1408.
11. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Wasicak J.T., Garvey D.S., Williams M., Arneric S.P. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270:1994;319-328.
12. Doods H., Entzeroth M., Ziegler H., Schiavi G., Engel W., Mihm G., Rudolf K., Eberlein W. Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur. J. Pharmacol. 242:1993;23-30.
13. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66:1999;137-147.
14. Ghelardini C., Galeotti N., Gualtieri F., Scapecchi S., Bartolini A. 3-α-Tropanyl 2-(4-Cl-phenoxy)butyrate (SM21): a review of the pharmacological profile of a novel enhancer of cholinergic transmission. CNS Drug Reviews. 3:1997;346-362.
15. Glennon R.A., Dukat M. Nicotine receptor ligands. Med. Chem. Res. 6:1996;465-486.
16. Gualtieri F., Dei S., Manetti D., M.N. R., Scapecchi S., Teodori E. The medicinal chemistry of Alzheimer and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. Il Farmaco. 50(7-8):1995;489-503.
17. Holladay M.K., Lebold S.A., Lin N.-H. Structure-activity relationships of nicotinic acetylcholine receptor agonists as potential treatments for dementia. Drug Dev. Res. 35:1995;191-213.
18. Holladay M.W., Dart M.J., Lynch J.K. Neuronal nicotinic acetylcholine receptors as target for drug discovery. J. Med. Chem. 40:1997;4169-4194.
19. Kelly J.S. Alzheimer's disease: the tacrine legacy. TIPS. 20:1999;127-129.
20. Lachowicz J.E., Lowe D., Duffy R.A., Rupero W., Taylor L.A., Guzik H., Brown J., Berger J.G., Tice M., McQuade R., Kozlowski J., Clader J., Strader C.D., Murgolo N. SCH 57790: a novel M2 receptor selective antagonist. Life Sciences. 64:1999;535-539.
21. McGeeer E.G. Neurotransmitter system in aging and dementia. Prog. Neuropsychopharmacol. 5:1981;435-445.
22. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1:1977;189.
23. Schenk D.B., Rydel R.E., May P., Little S., Panetta J., Lieberburg I., Sinha S. Therapeutic approaches related to amyloid beta-peptide and Alzheimer's disease. J. Med. Chem. 38:1995;4141-4154.